The White House denies a report suggesting President Donald Trump received retatrutide, an investigational obesity medication. Both outlets report that the White House response targets speculation that Trump could have obtained the drug through the FDA’s “compassionate use” pathway. Retatrutide is made by Eli Lilly and is not FDA approved, according to the reporting. MedPage Today says the White House “aggressively” denied the claim, which was based on information that Eli Lilly and the FDA granted one request related to compassionate use. The Hill similarly describes White House officials pushing back on the idea that Trump gained access via the FDA compassionate use program, noting that the drug remains investigational and that access in such programs is limited. The reports do not present new evidence from the White House beyond the denial itself, and they focus on clarifying whether any compassionate use authorization extended to Trump. Overall, the coverage centers on disagreement between a media report and the White House about whether Trump received the unapproved retatrutide drug.